Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Feb 23;160(4):483–488.

The cost of obesity in Canada

C L Birmingham 1, J L Muller 1, A Palepu 1, J J Spinelli 1, A H Anis 1
PMCID: PMC1230073  PMID: 10081464

Abstract

BACKGROUND: Almost one-third of adult Canadians are at increased risk of disability, disease and premature death because of being obese. In order to allocate limited health care resources rationally, it is necessary to elucidate the economic burden of obesity. OBJECTIVE: To estimate the direct costs related to the treatment of and research into obesity in Canada in 1997. METHODS: The prevalence of obesity (body mass index of 27 or greater) in Canada was determined using data from the National Population Health Survey, 1994-1995. Ten comorbidities of obesity were identified from the medical literature. A population attributable fraction (PAF) was calculated for each comorbidity with data from large cohort studies to determine the extent to which each comorbidity and its management costs were attributable to obesity. The direct cost of each comorbidity was determined using data from the Canadian Institute of Health Information (for direct expenditure categories) and from Health Canada (for the proportion of expenditure category attributable to the comorbidity). This prevalence-based approach identified the direct costs of hospital care, physician services, services of other health professionals, drugs, other health care and health research. For each comorbidity, the cost attributable to obesity was determined by multiplying the PAF by the total direct cost of the comorbidity. The overall impact of obesity was estimated as the sum of the PAF-weighted costs of treating the comorbidities. A sensitivity analysis was completed on both the estimated costs and the PAFs. RESULTS: The total direct cost of obesity in Canada in 1997 was estimated to be over $1.8 billion. This corresponded to 2.4% of the total health care expenditures for all diseases in Canada in 1997. The sensitivity analysis revealed that the total cost could be as high as $3.5 billion or as low as $829.4 million; this corresponded to 4.6% and 1.1% respectively of the total health care expenditures in 1997. When the contributions of the comorbidities to the total cost were considered, the 3 largest contributors were hypertension ($656.6 million), type 2 diabetes mellitus ($423.2 million) and coronary artery disease ($346.0 million). INTERPRETATION: A considerable proportion of health care dollars is devoted to the treatment and management of obesity-related comorbidities in Canada. Further research into the therapeutic benefits and cost-effectiveness of management strategies for obesity is required. It is anticipated that the prevention and treatment of obesity will have major positive effects on the overall cost of health care.

Full Text

The Full Text of this article is available as a PDF (121.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. American Health Foundation Roundtable on Healthy Weight. Proceedings of an expert panel discussion. New York, New York, September 20, 1994. Am J Clin Nutr. 1996 Mar;63(3 Suppl):409S–477S. doi: 10.1093/ajcn/63.3.409. [DOI] [PubMed] [Google Scholar]
  2. Ascherio A., Rimm E. B., Giovannucci E. L., Colditz G. A., Rosner B., Willett W. C., Sacks F., Stampfer M. J. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992 Nov;86(5):1475–1484. doi: 10.1161/01.cir.86.5.1475. [DOI] [PubMed] [Google Scholar]
  3. Breslow N. E., Day N. E. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ. 1980;(32):5–338. [PubMed] [Google Scholar]
  4. Colditz G. A. Economic costs of obesity. Am J Clin Nutr. 1992 Feb;55(2 Suppl):503S–507S. doi: 10.1093/ajcn/55.2.503s. [DOI] [PubMed] [Google Scholar]
  5. Colditz G. A., Willett W. C., Rotnitzky A., Manson J. E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995 Apr 1;122(7):481–486. doi: 10.7326/0003-4819-122-7-199504010-00001. [DOI] [PubMed] [Google Scholar]
  6. Felson D. T., Anderson J. J., Naimark A., Walker A. M., Meenan R. F. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. 1988 Jul 1;109(1):18–24. doi: 10.7326/0003-4819-109-1-18. [DOI] [PubMed] [Google Scholar]
  7. Felson D. T. The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. Semin Arthritis Rheum. 1990 Dec;20(3 Suppl 1):42–50. doi: 10.1016/0049-0172(90)90046-i. [DOI] [PubMed] [Google Scholar]
  8. Flegal K. M., Carroll M. D., Kuczmarski R. J., Johnson C. L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998 Jan;22(1):39–47. doi: 10.1038/sj.ijo.0800541. [DOI] [PubMed] [Google Scholar]
  9. Folsom A. R., Kaye S. A., Potter J. D., Prineas R. J. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res. 1989 Dec 1;49(23):6828–6831. [PubMed] [Google Scholar]
  10. Goldhaber S. Z., Grodstein F., Stampfer M. J., Manson J. E., Colditz G. A., Speizer F. E., Willett W. C., Hennekens C. H. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997 Feb 26;277(8):642–645. [PubMed] [Google Scholar]
  11. Gorstein J., Grosse R. N. The indirect costs of obesity to society. Pharmacoeconomics. 1994;5(Suppl 1):58–61. doi: 10.2165/00019053-199400051-00012. [DOI] [PubMed] [Google Scholar]
  12. Hodgson T. A., Meiners M. R. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982 Summer;60(3):429–462. [PubMed] [Google Scholar]
  13. Kato I., Nomura A., Stemmermann G. N., Chyou P. H. Prospective study of clinical gallbladder disease and its association with obesity, physical activity, and other factors. Dig Dis Sci. 1992 May;37(5):784–790. doi: 10.1007/BF01296440. [DOI] [PubMed] [Google Scholar]
  14. Koopmanschap M. A. Cost-of-illness studies. Useful for health policy? Pharmacoeconomics. 1998 Aug;14(2):143–148. doi: 10.2165/00019053-199814020-00001. [DOI] [PubMed] [Google Scholar]
  15. Laupacis A., Wells G., Richardson W. S., Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA. 1994 Jul 20;272(3):234–237. doi: 10.1001/jama.272.3.234. [DOI] [PubMed] [Google Scholar]
  16. Lee I. M., Manson J. E., Hennekens C. H., Paffenbarger R. S., Jr Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA. 1993 Dec 15;270(23):2823–2828. doi: 10.1001/jama.270.23.2823. [DOI] [PubMed] [Google Scholar]
  17. Lee I. M., Paffenbarger R. S., Jr Quetelet's index and risk of colon cancer in college alumni. J Natl Cancer Inst. 1992 Sep 2;84(17):1326–1331. doi: 10.1093/jnci/84.17.1326. [DOI] [PubMed] [Google Scholar]
  18. Leung H. M., Kupper L. L. Comparisons of confidence intervals for attributable risk. Biometrics. 1981 Jun;37(2):293–302. [PubMed] [Google Scholar]
  19. Lew E. A., Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979;32(8):563–576. doi: 10.1016/0021-9681(79)90119-x. [DOI] [PubMed] [Google Scholar]
  20. Lévy E., Lévy P., Le Pen C., Basdevant A. The economic cost of obesity: the French situation. Int J Obes Relat Metab Disord. 1995 Nov;19(11):788–792. [PubMed] [Google Scholar]
  21. Manson J. E., Nathan D. M., Krolewski A. S., Stampfer M. J., Willett W. C., Hennekens C. H. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA. 1992 Jul 1;268(1):63–67. [PubMed] [Google Scholar]
  22. Manson J. E., Willett W. C., Stampfer M. J., Colditz G. A., Hunter D. J., Hankinson S. E., Hennekens C. H., Speizer F. E. Body weight and mortality among women. N Engl J Med. 1995 Sep 14;333(11):677–685. doi: 10.1056/NEJM199509143331101. [DOI] [PubMed] [Google Scholar]
  23. Pi-Sunyer F. X. Medical hazards of obesity. Ann Intern Med. 1993 Oct 1;119(7 Pt 2):655–660. doi: 10.7326/0003-4819-119-7_part_2-199310011-00006. [DOI] [PubMed] [Google Scholar]
  24. Rabkin S. W., Chen Y., Leiter L., Liu L., Reeder B. A. Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group. CMAJ. 1997 Jul 1;157 (Suppl 1):S26–S31. [PubMed] [Google Scholar]
  25. Rexrode K. M., Hennekens C. H., Willett W. C., Colditz G. A., Stampfer M. J., Rich-Edwards J. W., Speizer F. E., Manson J. E. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997 May 21;277(19):1539–1545. doi: 10.1001/jama.1997.03540430051032. [DOI] [PubMed] [Google Scholar]
  26. Rimm E. B., Stampfer M. J., Giovannucci E., Ascherio A., Spiegelman D., Colditz G. A., Willett W. C. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995 Jun 15;141(12):1117–1127. doi: 10.1093/oxfordjournals.aje.a117385. [DOI] [PubMed] [Google Scholar]
  27. Segal L., Carter R., Zimmet P. The cost of obesity: the Australian perspective. Pharmacoeconomics. 1994;5(Suppl 1):45–52. doi: 10.2165/00019053-199400051-00009. [DOI] [PubMed] [Google Scholar]
  28. Seidell J. C., Bakx K. C., Deurenberg P., van den Hoogen H. J., Hautvast J. G., Stijnen T. Overweight and chronic illness--a retrospective cohort study, with a follow-up of 6-17 years, in men and women of initially 20-50 years of age. J Chronic Dis. 1986;39(8):585–593. doi: 10.1016/0021-9681(86)90183-9. [DOI] [PubMed] [Google Scholar]
  29. Seidell J. C., Deerenberg I. Obesity in Europe: prevalence and consequences for use of medical care. Pharmacoeconomics. 1994;5(Suppl 1):38–44. doi: 10.2165/00019053-199400051-00008. [DOI] [PubMed] [Google Scholar]
  30. Seidell J. C. The impact of obesity on health status: some implications for health care costs. Int J Obes Relat Metab Disord. 1995 Nov;19 (Suppl 6):S13–S16. [PubMed] [Google Scholar]
  31. Seidell J. C. Time trends in obesity: an epidemiological perspective. Horm Metab Res. 1997 Apr;29(4):155–158. doi: 10.1055/s-2007-979011. [DOI] [PubMed] [Google Scholar]
  32. Sellers T. A., Kushi L. H., Potter J. D., Kaye S. A., Nelson C. L., McGovern P. G., Folsom A. R. Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med. 1992 May 14;326(20):1323–1329. doi: 10.1056/NEJM199205143262004. [DOI] [PubMed] [Google Scholar]
  33. Stampfer M. J., Maclure K. M., Colditz G. A., Manson J. E., Willett W. C. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr. 1992 Mar;55(3):652–658. doi: 10.1093/ajcn/55.3.652. [DOI] [PubMed] [Google Scholar]
  34. Swinburn B., Ashton T., Gillespie J., Cox B., Menon A., Simmons D., Birkbeck J. Health care costs of obesity in New Zealand. Int J Obes Relat Metab Disord. 1997 Oct;21(10):891–896. doi: 10.1038/sj.ijo.0800486. [DOI] [PubMed] [Google Scholar]
  35. Willett W. C., Manson J. E., Stampfer M. J., Colditz G. A., Rosner B., Speizer F. E., Hennekens C. H. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA. 1995 Feb 8;273(6):461–465. doi: 10.1001/jama.1995.03520300035033. [DOI] [PubMed] [Google Scholar]
  36. Witteman J. C., Willett W. C., Stampfer M. J., Colditz G. A., Sacks F. M., Speizer F. E., Rosner B., Hennekens C. H. A prospective study of nutritional factors and hypertension among US women. Circulation. 1989 Nov;80(5):1320–1327. doi: 10.1161/01.cir.80.5.1320. [DOI] [PubMed] [Google Scholar]
  37. Wolf A. M., Colditz G. A. The cost of obesity: the US perspective. Pharmacoeconomics. 1994;5(Suppl 1):34–37. doi: 10.2165/00019053-199400051-00007. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES